PANEL DISCUSSION: The JAK Class Black Box Warning: The Implications for the JAK Inhibitor Drug Development Landscape for Dermatology & Beyond

Time: 10:00 am
day: Day Two


  • Cataloguing the implications across numerous disciplines the FDA issued JAK black box warning will have just as pharma was beginning to realise the potential the JAK/STAT pathway holds.
  • Evaluating where the community sees the market potential for JAK inhibitors within the pharmaceutical industry despite the warning.
  • Discussing ways in which companies may begin marketing their JAK inhibitors whilst also debating the demand for novel therapeutic options in underserved indications, where benefit-risk calculations must take place.